We will be closed on July 4th for Independence Day 🇺🇸 No shipping on July 3rd!

 More Info 

SAVE 10% OFF First Order With Coupon Code: WELCOME10


Call Toll Free

SAVE 10% OFF First Order With Coupon Code: WELCOME10


Humira (Adalimumab)

2 pens for $2,150.00

Humira Autoinjector - 40mg/0.8mL



Humira is a brand-name medication that acts as a TNF blocker that lowers your immune system’s ability to fight infections. Humira is one of the most expensive medications in the United States. However, you can purchase it through Canada for substantially less.

By targeting and blocking a source of inflammation caused by moderate to severe Crohn’s disease, Humira can help many adults achieve and maintain remission.

Inflammation can be reduced by using Humira (adalimumab), which works as a tumor necrosis factor (TNF) blocker.

Among the conditions for which Humira is used are rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa, a skin condition.

The injection is administered by injection under the skin (similar functionality as Trulicity pens). You can distribute it yourself in the comfort of your own home, either by a Pen or a prefilled syringe.

Before Taking Humira

If you are allergic to adalimumab, you should not use Humira.

If you experience any of these symptoms of infection before starting this medication-fever, chills, sweats, muscle aches, tiredness, cough, bloody mucus, skin sores, diarrhea, burning when you urinate, or feeling constantly tired-tell your doctor.

Children younger than 2 years old (or 6 years old if the child has Crohn’s disease) should not be given Humira. Before starting treatment with this medicine, all childhood vaccinations should be up-to-date.

Let your doctor know if you have ever had:

● tuberculosis (or if you know anyone with tuberculosis);

â—Ź a chronic infection;

â—Ź cancer;

â—Ź hepatitis B (adalimumab can cause hepatitis B to come back or get worse);

â—Ź diabetes;

â—Ź heart failure;

â—Ź numbness or tingling, or any disorder of the nerve or muscle, such as multiple sclerosis or Guillain-Barre syndrome;

â—Ź an allergy to latex rubber;

â—Ź if you are scheduled to have major surgery; or

â—Ź if you have recently received or are scheduled to receive any vaccine.

Humira may cause a rare type of blood cancer (lymphoma) that can kill the liver, spleen, and bone marrow. Typically, this occurs in teenagers and young men with Crohn’s disease or ulcerative colitis. People with inflammatory autoimmune disorders, however, may be at greater risk of lymphoma. Discuss your risk with your doctor.

There is no information on the risk to an unborn baby of this medicine. Consult your physician before taking this medication. If you used adalimumab while pregnant, let any doctor caring for your newborn know. For more information, see the pregnancy tab.

While you are taking this medicine, you may not be able to breastfeed a baby. Discuss any risks with your doctor.

Warnings and Precautions

Before using Humira, inform your doctor if you have any allergies. This medication may contain ingredients such as latex or natural rubber that may trigger an allergic reaction. Consult your pharmacist as well.

Before starting Humira, inform your doctor of your medical histories such as recent/current/repeated infections such as TB infection, histoplasmosis or hepatitis B; blood bone marries problems (such as low white/red blood cells or platelets), certain brain/nerve disorders (such as MS, Guillain-Barre syndrome), heart disease, cancer, diabetes or lupus.

Wash your hands thoroughly to prevent the spread of infections. Humira may increase your chances of getting infections or worsening conditions. Inform your doctor if you have been exposed to an infection and avoid contact with people with measles, chickenpox, or have the flu.

Consult your doctor if you are looking to get any vaccinations or immunizations, and avoid people who have recently received vaccinations.

Be attentive when using sharp objects such as razors and nail cutters to avoid getting cut, bruised, or injured. Avoid contact sports.

Inform your doctor about all medications you are currently taking, including over-the-counter drugs, herbal supplements, and other prescription medications.

Let your doctor know if you plan on getting pregnant or pregnant if you are using or planning to use Humira. Humira should only be used if needed during pregnancy. Speak to your doctor about the risks and benefits of taking Humira.

Since this medication passes through breast milk, you should consult your doctor before breastfeeding.

Older adults are at an increased risk of infections while using this medication.

As a result of taking this drug, your immune system is affected. You may become more susceptible to infection since adalimumab decreases your immune system’s ability to fight infections. In people taking this medicine, severe conditions have been caused by viruses, fungi, and bacteria.

Among the severe infections is tuberculosis (TB). You should be tested for TB before and during treatment with this medication..

General Consideration

In addition to consulting your physician, Humira is intended for use under medical supervision. 

When a physician determines that it is appropriate, a patient or caregiver may inject Humira using either the Humira Pen or prefilled syringe after proper training in subcutaneous injection technique.

Prior to subcutaneous administration, thoroughly inspect the solution in the Humira Pen, prefilled syringe, or single-dose institutional use vial for particulate matter and discoloration. Don’t use the product if you notice particulates or discolorations. Because Humira does not contain preservatives, any remaining medication from the syringe should be discarded. Latex-sensitive patients should not handle the needle cover of the Humira 40 mg/0.8 mL Pen and the Humira 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe, as it may contain natural rubber latex.

Each injection should be administered at a different site in the thigh or abdomen. Don’t inject into tender, bruised, red or hard areas of the skin. Rotate injection sites. Immediately administer missed doses. Continue regular dosing thereafter. Humira is available in single-dose institutional vials for use in hospitals, physician’s offices, and clinics only. Use a sterile needle and syringe to withdraw the dose and administer it promptly by a healthcare provider within an institutional setting. Only administer one dose per vial. The vial does not contain preservatives; therefore, discard unused portions.

Humira Injection Sites


Humira is a tumor necrosis factor (TNF) blocker indicated for the treatment of

Rheumatoid Arthritis

Reducing signs and symptoms, inducing primary clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.

Juvenile Idiopathic Arthritis

Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients two years of age and older.

Psoriatic Arthritis

Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.

Ankylosing Spondylitis

Reducing signs and symptoms in adult patients with active AS.

Adult Crohn’s Disease

Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Pediatric Crohn’s Disease

Reducing signs and symptoms and inducing and maintaining clinical remission in patients six years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

Ulcerative Colitis

Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine (6-MP). The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.

Plaque Psoriasis

The treatment of adult patients with moderate to severe chronic plaque psoriasis candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.


The treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Hidradenitis Suppurativa

In adults 12 years of age and older, Humira is indicated to treat moderate to severe hidradenitis suppurativa.

Serious Infections


In patients receiving Humira, including those who have previously received treatment for latent or active tuberculosis, cases of reactivation of tuberculosis and new onset tuberculosis infections have been reported. Several cases of pulmonary and extrapulmonary (i.e., disseminated) tuberculosis were reported. Prior to initiating Humira, and periodically during treatment, evaluate patients for tuberculosis risk factors and test for latent infection.

Treatment of latent tuberculosis infection with TNF blocking agents before therapy has been shown to reduce the risk of tuberculosis reactivation during therapy. Assess the need for latent tuberculosis treatment before starting Humira; and consider an induration of * 5 mm a positive tuberculin skin test result, even if the patient has been previously vaccinated with Bacille Calmette-Guerin (BCG). In patients with a history of latent or active tuberculosis, and in patients with a negative test for latent tuberculosis but risk factors for tuberculosis infection, consider anti-tuberculosis therapy before initiating Humira. Despite prophylactic treatment for tuberculosis, patients treated with Humira have developed reactivated tuberculosis. In determining whether to initiate antituberculosis therapy, patients should consult with a physician with expertise in the treatment of tuberculosis. When a patient develops a new infection during treatment with Humira, strongly consider tuberculosis, especially if the patient has recently traveled to a country where tuberculosis is prevalent or if he or she has had contact with an active tuberculosis patient.


Monitor patients closely during and after treatment with Humira for the development of signs and symptoms of infection, including the development of tuberculosis in patients who did not have latent tuberculosis infection. When taking Humira, tests for latent tuberculosis infection may also be falsely negative. A patient should stop taking Humira if they develop a serious infection or sepsis. An immunocompromised patient who develops an infection during treatment with Humira should be closely monitored, undergo an appropriate diagnostic workup, and be prescribed appropriate antimicrobial therapy.

Invasive Fungal

Consider invasive fungal infection in the differential diagnosis if patients have a serious systemic illness and reside in regions where mycoses are endemic. Some patients with active histoplasmosis may test negative for antigens and antibodies. As part of a diagnostic workup, consider appropriate empiric antifungal therapy, taking into account both the risk of severe fungal infection and the risk of antifungal therapy. Consider consulting with a physician skilled in the diagnosis and treatment of invasive fungal infections to assist in the management of such patients.


Humira should be used according to your doctor’s instructions. Read all medication guides or instruction sheets and follow the directions on your prescription label. Follow the instructions precisely.

Injecting Humira under the skin is the procedure. A healthcare provider administers this medicine.

If your medicine comes with an instruction sheet, read and follow it carefully. Humira should not be used if you cannot understand its instructions.

If you have any inquiries or need more information, please do not hesitate to reach out to your healthcare professional.

Humira dosage schedules depend on the condition being treated and treated. Always follow the directions given by your doctor carefully.

If you are not ready to administer your injection, do not prepare it. If the medicine is cloudy, colored differently, or contains particles, it shouldn’t be used. Contact your pharmacist to get a new treatment.

Humira impacts immunity. You may become more prone to infections, including severe or fatal diseases. Regular medical care may be necessary.

The original carton of this medicine should be kept in the refrigerator. Avoid freezing. Follow all patient instructions regarding travel medicine storage carefully if you are traveling. Keep away from extremes of temperature. Any Humira that has frozen should be thrown away.

Put needles and syringes in a sharps container after using them only once. Dispose of it by local or state regulations. Avoid having children or pets around it.


A typical adult dose of Humira for psoriatic arthritis is as follows:

Every other week, 40 mg subcutaneously

The interval between doses may be increased to 40 mg every week in some patients not taking concomitant methotrexate.

Concomitantly, methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, analgesics, or other disease-modifying agents may be given.

Dose for Crohn’s Disease in Adults -Acute:

The initial dose is 160 mg subcutaneously on Day 1. In the initial dose, 4 injections may be given on Day 1 or 2 injections per day for two consecutive days (Days 1 and 2).

In Week 2, 80 mg is administered ssubcutaneously. The maintenance dose will be 40 mg every other week beginning on week 4 (Day 29).g every other week.

During treatment with adalimumab, aminosalicylates, corticosteroids, and immunomodulatory agents may be continued.

The use of adalimumab for Crohn’s disease beyond one year had not been evaluated in controlled clinical studies.

Humira dosage for Crohn’s disease maintenance in adults:

The initial dose is 160 mg subcutaneously on Day 1. The initial dose may be administered as four injections on Day 1 or as two injections per day for two days (Days 1 and 2).

On Day 15 of Week 2, administer 80 mg subcutaneously.

The maintenance dose is 40 mg every other week beginning in week 4 (Day 29).

Humira may be taken along with aminosalicylates, corticosteroids, or immunomodulators.

Controlled clinical studies have not evaluated the use of adalimumab for Crohn’s disease beyond one year.

The usual adult dose for ulcerative colitis is:

The initial dose is 160 mg subcutaneously on Day 1. The initial dose may be administered as four injections on Day 1 or as two injections per day for two days (Days 1 and 2).

On Day 15 of Week 2, administer 80 mg subcutaneously.

The maintenance dose is 40 mg every other week beginning in week 4 (Day 29).

During treatment with Humira, aminosalicylates, corticosteroids, and/or immunomodulators may be continued.

It has not been evaluated in controlled clinical trials whether adalimumab should be used beyond one year for Crohn’s disease.

Plaque Psoriasis Adult Dose:

The initial dose is 80 mg subcutaneously.

Starting one week after the initial dose, administer 40 mg subcutaneously every other week.

A typical pediatric dose for juvenile idiopathic arthritis is:

There is limited data available for Humira treatment in pediatric patients weighing less than 15 kg between the ages of 4 and 17.

20 mg every other week for those weighing 15 kg to 30 kg (66 lbs).

More than or equal to 30 kg (66 lbs): 40 mg every other week

During treatment with Humira, methotrexate, glucocorticoids, salicylates, NSAIDs, or analgesics may be continued.

Side Effects

If you experience severe side effects related to taking Humira, consult your doctor immediately. If you feel the symptoms are life-threatening, seek a medical emergency by calling 911.

Serious side effects experienced by patients taking Humira include heart failure, which has the symptoms of sudden weight gain, shortness of breath, swelling of feet and ankles.

Another severe side effect is Lupis-like syndrome which may have the symptoms of shortness of breath, joint pain, discomfort or pain in the chest, and rashes on arms and chest that worsen in the sun.

Nerve disorders or demyelinating diseases such as multiple sclerosis or seizures are also possible side effects.  The symptoms include vision problems, dizziness, tingling or numbness, weakness in the arms or legs.

Blood disorders such as anemia should also be monitored. They have the symptoms of bleeding, bruising, the appearance of pale skin, and long-lasting fevers.

This medication has also been linked to liver damage. The symptoms of liver damage include stomach ache, loss of appetite, vomiting, and jaundice.

Drug Interactions

Taking adalimumab with certain medications is not recommended. During your treatment with Humira, be sure to tell your doctor about all medicines you take, and these include:

● Atacept and Etanercept;
● Anakinra;
● And azathioprine or 6-mercaptopurine
â—Ź Rituximab, certolizumab, golimumab, and infliximab.

These are not the only medications available. Additionally, adalimumab may interact with other drugs, including over-the-counter medicines, vitamins, and herbal products.

This medication guide does not list all possible interactions.


Available studies using adalimumab during pregnancy do not reliably establish an association between adalimumab and significant congenital disabilities.

Clinical data are available from the Organization of Teratology Information Specialists (OTIS)/MotherToBaby Humira Pregnancy Registry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD). Registry results showed a rate of 10% for significant congenital disabilities with first-trimester use of adalimumab in pregnant women with RA or CD and 7.5% for significant congenital disabilities in the disease-matched comparison cohort.

The lack of pattern of significant congenital disabilities is reassuring, and differences between exposure groups may have impacted the occurrence of congenital disabilities. Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in-utero exposed infant. In an embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm or malformations were observed with intravenous administration of adalimumab during organogenesis and later in gestation, at doses that produced exposures up to approximately 373 times the maximum recommended human dose (MRHD) of 40 mg subcutaneous without methotrexate (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Limited data from case reports in the published literature describe the presence of adalimumab in human milk at infant doses of 0.1% to 1% of the maternal serum concentration. Published data suggest that the systemic exposure to a breastfed infant is expected to be low because adalimumab is a large molecule and is degraded in the gastrointestinal tract. However, the effects of local exposure in the gastrointestinal tract are unknown. There are no reports of adverse effects of adalimumab on the breastfed infant and no effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Humira and any potential adverse effects on the breastfed child from Humira or from the underlying maternal condition.


Humira must be kept cold and stored in the refrigerator. It is delivered in an insulated container to maintain its integrity.

Please keep it in its original packaging until ready for use.

Do not freeze or ever use if it was previously frozen.

Keep the medication away from direct sunlight.

When ready to use, take it out of the refrigerator and let it naturally warm up. Do not try to warm it up faster.

When traveling or not able to keep medication cold, Humira can be stored at room temperature (up to 77 degrees) for up to 2 weeks. Humira can be retained unrefrigerated for up to 14 days. If it exceeds two weeks or this temperature, d not use.

When disposing of medication, do not flush down wastewater (i.e., toilet or sink) or put it in household trash. Discard this medication according to your pharmacist’s instructions when expired or no longer needed.

Humira disposal


In clinical trials, doses up to 10 mg/kg have been administered without evidence of dose-limiting toxicities. If a patient has overdosed, it is recommended that they be monitored for any signs or symptoms of adverse reactions or effects and that they be treated immediately.

Customer Reviews